CONFERENCE AGENDA

Registration

08:15 - 08:55

Welcome note from MarketsandMarkets

08:55 - 09:00

Opening remarks from the Chairman Frank Borriello, Founder and CEO, Alloplex Biotherapeutics	09:00 - 09:05
Keynote: Mutations in the IL-7 receptor driving acute lymphoblastic leukemia Scott Durum, Head, Cytokines and Immunity, NIH	09:05 - 09:40
Natural single domain antibodies as potential alternatives to monoclonal antibodies in the next generation immunotherapy Rajesh Singh, Laboratory Director, Abzyme Therapeutics	09:40 - 10:15
Screening the Membrane Proteome to Determine Antibody Specificity and Discover New Immunomodulatory Targets Tabb Sullivan, Senior Scientist, Project Leader, Integral Molecular	10:15 - 10:50
Morning Refreshments and Poster Presentations \| One-to-One Networking Meetings	10:50 - 11:40
Targeted Antibodies and Combinations
Learnings from the successful Cancer Immunotherapy Combinations and Bispecifics Rakesh Dixit, CEO, Bionavigen	11:40 - 12:15
Human Cell Culture: The Role of In Vitro models in Cancer Immunotherapy Development Melissa Olekson, Scientific Support Specialist, PromoCell	12:15 - 12:50
Therapeutic targeting of the tumor microenvironment	12:25 - 12:55
ex vivo PBMC Activation of Antitumor Activity Offers Accelerated Path to Clinical Application Frank Borriello, Founder and CEO, Alloplex Biotherapeutics	12:50 - 13:25
Lunch and Poster Presentations \| One-to-One Networking Meetings	13:25 - 14:25
New Antibody Formats and Developments in CAR-T Cell Therapy
Biomarkers Associated with Clinical Outcomes in ZUMA-1 Supporting Approval of Yescarta Vicki Plaks, Translational Lead, Principal Scientist, Translational Sciences, Kite Pharma	14:25 - 15:00
Improving the Safety and Efficacy Profile of CAR-T: GM-CSF Neutralization with Lenzilumab	15:00 - 15:35
Next-generation gene editing technology for allogeneic T cell therapeutics Megan van Overbeek, Associate Director of Functional Genomics, Caribou Biosciences	15:35 - 16:10
Evening Refreshments and Poster Presentations \| One-to-One Networking Meetings	16:10 - 16:45
“RubrYc Therapeutics: Overcoming Immunodominance to Discover Next Gen Biotherapeutics” Matt Greving, Co-Founder & VP, Technology, RubrYc Therapeutics Inc.	16:45 - 17:20
Closing remarks from the Chairman	17:20 - 17:25
Cocktail Reception \| End of Day 1	17:30 - 17:35

Opening remarks from the Chairman Shahram Salek-Ardakani, Chief Scientific Officer, Janux Therapeutics	09:00 - 09:05
Keynote: Defining T Cell States Associated with Response to Combination Immunotherapy Shahram Salek-Ardakani, Chief Scientific Officer, Janux Therapeutics	09:05 - 09:40
Breast Cancer Immunotherapy: Novel Combinations of Bria-IMT™ with Checkpoint Inhibitors William Williams, President, CEO, Briacell Therapeutics Corporation	09:40 - 10:15
Accelerating Therapeutic Antibody Discovery and Development with Innovative Humanized Mouse Models Qingcong Lin, Senior Vice President, CEO, Biocytogen Boston Corporation	10:15 - 11:40
Pre-clinical & Translational Immuno-Oncology Developments
Reversing trastuzumab resistance in HER2+ breast cancer RJ Tesi, CEO, CMO, INmune Bio Inc.	11:40 - 12:15
Humanized Mouse Models for Immuno-Oncology Research Sebastien Tabruyn, Chief Scientific Officer, Transcure Bioservices	12:15 - 12:50
Preserving CTLA4 function to make a better and safer anti-CTLA4 antibody Pan Zheng, Professor, University of Maryland School of Medicine	12:50 - 14:25
New Immune Checkpoints for Immunotherapy
Clinical development of GITR based immunotherapies Girish Naik, Medical Director, Leap Therapeutics	14:25 - 15:00
B cells in the human tumor microenvironment Tullia Bruno, Assistant Professor, Immunology, University of Pittsburgh	15:35 - 16:05
Evening Refreshments and Poster Presentations \| One-to-One Networking Meetings	16:05 - 16:55
Break out Session: Future of Biologics in Immune Checkpoint therapy	16:55 - 17:20
Closing remarks from the Chairman	17:20 - 17:25

Registration

08:15 - 08:55

Opening remarks from the Chairman Emmanuel Normant, Vice President, Preclinical Sciences, TG Therapeutics	09:00 - 09:05
New Antibodies Development and Tumor Microenvironment
Keynote: Anti PD-! Antibodies are Transforming Cancer Care both as Mono- and Combination Therapy Roy Baynes, Executive Vice President, Chief Medical Officer, Eikon Therapeutics	09:05 - 09:40
Combinations of antibodies and small molecules in the Immuno-Oncology world: A TG Therapeutics perspective Emmanuel Normant, Vice President, Preclinical Sciences, TG Therapeutics	09:40 - 10:15
Targeting Immunosuppressive Sialoglycans in the Tumor Microenvironment Using A Novel Therapeutic Modality EAGLE Li Peng, Senior Vice President, Palleon Pharma	10:15 - 10:50
Morning Refreshments and Poster Presentations \| One-to-One Networking Meetings	10:50 - 11:40
Novel T cell engaging bispecific antibodies for cancer immunotherapy Thomas Tan, Vice President, Immunology, Elstar Therapeutics	11:40 - 12:15
B7-H3, an attractive target of antibody-based immunotherapy Soldano Ferrone, Professor of Surgery, Massachusetts General Hospital, Harvard Medical School	12:15 - 12:50
Comparing immunological marker signatures across various cancer types Natalie Russi, Scientific Project Manager, Nebion	12:50 - 13:25
End of Conference	13:00 - 13:05
Closing remarks from the Chairman	13:25 - 13:30

Opening remarks from the Chairman Stefan Glueck, Senior Vice President, Global Medical Affairs, Celgene	09:00 - 09:05
Personalized Immunotherapy and T-Cell Therapies
Keynote: Tumor Inflammatory Signature Carl Morrison, President, Chief Medical Officer, OmniSeq	09:05 - 09:40
Development of effective immunotherapeutic combinations with antitumor activities Joost Oppenheim, Head, Cellular Immunology, NIH	09:40 - 10:15
Update on ICI data in early and metastatic breast cancer Stefan Glueck, Senior Vice President, Global Medical Affairs, Celgene	10:15 - 10:50
End of Conference	13:00 - 13:05
Closing remarks from the Chairman	13:25 - 13:30